Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Flyte Aviation, Inc.RMED · Entity 8648 | Co-President | November 20, 2020 | November 24, 2020 |
| Saleen Automotive, Inc.SLNN · Entity 153727 | Director | April 09, 2019 | April 10, 2019 |
| Theriva Biologics, Inc.TOVX · Entity 7919 | Director | January 05, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Flyte Aviation, Inc.
Report date November 20, 2020 · Filed November 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,533 |
Reported balance
After 2020-11-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-20 · Grant · Acquired 200 · Balance 5,533 F1: These shares were acquired through the issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 128,006. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired through the issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 128,006.
Saleen Automotive, Inc.
Report date April 09, 2019 · Filed April 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 575,000 |
Reported balance
Holding disclosure · report date 2019-04-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 575,000 |
Theriva Biologics, Inc.
Report date January 05, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.24 · Expires 2033-01-04 | Direct | 75,000 |
Reported balance
After 2026-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-05 · Grant · Acquired 75,000 · Balance 75,000 F1: These stock options vest pro rata on a monthly basis over 12 months. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options vest pro rata on a monthly basis over 12 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2026 Filed Jan 6, 2026 21:53 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | GrantStock Options (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001104659-26-001383 · tm262266-2_4seq1.xml · derivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-04 F1 · shares: These stock options vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 12 months. Read SEC document |
| April 29, 2025 Filed May 1, 2025 20:01 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | GrantStock Options (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001104659-25-043507 · tm2513725-1_4seq1.xml · derivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-04-29 F1 · shares: These stock options vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 12 months. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 21:00 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | GrantStock Options (right to buy) · Derivative | 110,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-126371 · tm2332964-3_4seq1.xml · derivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2030-12-14 F1 · shares: These stock options vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 12 months. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 23:17 UTC | Theriva Biologics, Inc. TOVX · Entity 7919 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001104659-22-127975 · tm2232925-5_4seq1.xml · derivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-12-15 F1 · shares: These stock options vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 12 months. Read SEC document |
| December 23, 2021 Filed Dec 27, 2021 22:03 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001104659-21-153627 · tm2136313-1_4seq1.xml · derivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-12-23 F1 · shares: These stock options vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These stock options vest pro rata on a monthly basis over 12 months. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 21:30 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 150,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-20-140991 · tm2039654d1_4seq1.xml · derivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-12-30 F1 · shares: These stock options will vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These stock options will vest pro rata on a monthly basis over 12 months. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 16:37 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantCommon Stock | 200 | $5.43 | $1,086.30 |
DisclosureSEC source: 0001209191-20-060220 · doc4.xml · nonDerivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,533 F1 · shares: These shares were acquired through the issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · balance_after: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 128,006. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:14 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | PurchaseWarrants (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-20-045195 · doc4.xml · derivative · entry 2 Kraws Jeffrey J · CIK 0001380918 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2025-08-04 Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:14 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | PurchaseCommon Stock | 10,000 | $0.35 | $3,500.00 |
DisclosureSEC source: 0001209191-20-045195 · doc4.xml · nonDerivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,339 Read SEC document |
| May 22, 2020 Filed May 27, 2020 17:08 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | PurchaseCommon Stock | 10,000 | $0.46 | $4,600.00 |
DisclosureSEC source: 0001209191-20-032338 · doc4.xml · nonDerivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,339 Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 16:06 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | Tax withholdingCommon Stock | 792 | $0.90 | $713.59 |
DisclosureSEC source: 0001209191-19-061922 · doc4.xml · nonDerivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,339 F1 · kind: Shares withheld by the issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. This is not an open market sale of securities. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 18:23 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | Tax withholdingCommon Stock | 38,372 | $1.82 | $69,909.95 |
DisclosureSEC source: 0001209191-19-059371 · doc4.xml · nonDerivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,131 F1 · kind: Shares withheld by the issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. This is not an open market sale of securities. F2 · price: Represents the weighted share price of an aggregate total of 38,372 shares withheld in the price range of $1.69 to $1.96 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares withheld at each separate price. F3 · balance_after: Of the reported shares 2,315 shares are represented by Restricted Stock Units. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 12:13 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 250,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-19-070375 · tm1923941d3_form4.xml · derivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2026-12-04 F1 · shares: These stock options vest as follows: 1/3 will vest on the one year anniversary of the grant date, 1/3 will vest on the two year anniversary of the grant date and the remaining 1/3 will vest on the three year anniversary of the grant date. F1 · derivative.exercise_date: These stock options vest as follows: 1/3 will vest on the one year anniversary of the grant date, 1/3 will vest on the two year anniversary of the grant date and the remaining 1/3 will vest on the three year anniversary of the grant date. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 18:23 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantStock Option (Right to Buy) · Derivative | 139,052 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-19-059371 · doc4.xml · derivative · entry 2 Kraws Jeffrey J · CIK 0001380918 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,052 Underlying: Common Stock · 139,052 shares Expires 2029-12-03 F4 · derivative.exercise_date: 1/36 of the total shares subject to the option shall vest every month after December 3, 2019, such that all shares shall be fully vested on December 3, 2022, subject to the Reporting Person continuing to be a "Service Provider" (as defined in the Company's 2018 Equity Incentive Plan) through each vesting date. Read SEC document |
| July 18, 2019 Filed Jul 23, 2019 11:50 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | SaleCommon Stock | 11,930 | $2.93 | $34,971.60 |
DisclosureSEC source: 0001209191-19-042949 · doc4.xml · nonDerivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,503 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Reporting Person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Of the reported shares 92,384 shares are represented by Restricted Stock Units. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 17:25 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | SaleCommon Stock | 18,021 | $3.08 | $55,438.00 |
DisclosureSEC source: 0001209191-19-037452 · doc4.xml · nonDerivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,433 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Reporting Person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Of the reported shares 136,297 shares are represented by Restricted Stock Units. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:02 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 79,500 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001144204-18-063630 · tv508648_4.xml · derivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2025-12-06 F1 · shares: These options will vest monthly on a pro rata basis over 36 consecutive months. F1 · derivative.exercise_date: These options will vest monthly on a pro rata basis over 36 consecutive months. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 22:20 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001144204-17-064828 · tv481802_4.xml · derivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2024-12-19 F1 · shares: These stock options vest in full on the one year anniversary of the grant date. F1 · derivative.exercise_date: These stock options vest in full on the one year anniversary of the grant date. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 22:52 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | Exercise / conversionStock Options (right to buy) · Derivative | 228,773 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001144204-17-015198 · v462045_4.xml · derivative · entry 2 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 228,773 shares Expires 2017-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects a 1-for-3 reverse stock split effected in 2007. F1 · shares: Reflects a 1-for-3 reverse stock split effected in 2007. F1 · derivative.exercise_date: Reflects a 1-for-3 reverse stock split effected in 2007. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 22:52 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | Exercise / conversionCommon Stock | 228,773 | $0.09 | $20,589.57 |
DisclosureSEC source: 0001144204-17-015198 · v462045_4.xml · nonDerivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:03 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 168,750 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001144204-16-137739 · v454260_4.xml · derivative · entry 1 Kraws Jeffrey J · CIK 0001380918 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2023-11-29 F1 · shares: These stock options vest as follows: 1/3 vested on the grant date, 1/3 will vest on the one year anniversary of the grant date and the remaining 1/3 will vest on the two year anniversary of the grant date. F1 · derivative.exercise_date: These stock options vest as follows: 1/3 vested on the grant date, 1/3 will vest on the one year anniversary of the grant date and the remaining 1/3 will vest on the two year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.